Virginia Commonwealth University

VCU Scholars Compass
Undergraduate Research Posters

Undergraduate Research Opportunities Program

2017

Improving binding affinity through cyclization
Kaylee M. Newcomb
Virginia Commonwealth University

Nicolas Abrigo
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/uresposters
Part of the Medicinal-Pharmaceutical Chemistry Commons
© The Author(s)

Downloaded from
Newcomb, Kaylee M. and Abrigo, Nicolas, "Improving binding affinity through cyclization" (2017). Undergraduate Research Posters.
Poster 234.
https://scholarscompass.vcu.edu/uresposters/234

This Book is brought to you for free and open access by the Undergraduate Research Opportunities Program at VCU Scholars Compass. It has been
accepted for inclusion in Undergraduate Research Posters by an authorized administrator of VCU Scholars Compass. For more information, please
contact libcompass@vcu.edu.

Improving binding affinity through cyclization
Kaylee Newcomb, Nicolas Abrigo, Matthew C.T. Hartman
Virginia Commonwealth University, Richmond, VA, USA

1. Introduction
Background and Significance

3. Methods

Most cancer chemotherapy makes patients
sick because the drugs used are toxic to
normal tissues as well.
If one could
selectively sensitize a cancer cell to
chemotherapy or radiation, patients could
receive lower doses of the chemotherapy,
which in turn would reduce this unwanted
toxicity. Since many types of cancer
chemotherapy and radiation cause DNA
damage, one way to sensitize a cancer cell to
therapy is by interfering with the
mechanisms by which it repairs DNA. Work
from the Hartman lab developed a peptide
that binds with moderate affinity (KD of
1μM) to the C-terminal (BRCT)2 domain of
1
breast cancer associated protein (BRCA1).
This protein is a critical component of DNA
repair by homologous recombination.

Synthesis of linkers (Fig. 2)
-monitored by thin layer chromatography
-purified through column chromatography
-final products confirmed by 1H and 13C
NMR.

Figure 2. Synthesis of 1,4-bis(bromo)methylnaphthalene

Methods cont.

4. Discussion
Why use dibromomethylnaphthalene
linkers?
2
- Very robust, easy to cyclize with cysteines
- mRNA display compatible (can use this
cyclization strategy for future targets)
- Attaching the bromomethyl groups at
different locations of the naphthalene ring
provides variability in size

A

The 7th residue in the sequence was changed
from aspartate to asparagine to avoid
aspartimide formation during synthesis.

B

5. Future Direction

Table 1. Synthesized and commercially purchased
linkers used to cyclize

The binding of the cyclic peptides with
BRCA1 (BRCT)2 domain will be compared to
peptide 8.6 through the use of fluorescence
polarization.

2. Hypothesis
The crystal structure of peptide 8.6
(MCTIDFDEYRFRKT) bound to BRCA1
(BRCT)2 domain shows that the side chains
of the underlined tyrosine and threonine
residues are close together (Fig. 1). Our
hypothesis is that by cyclizing these
positions, the peptide may become
constrained into its bound conformation.
We used a bis-cysteine mutant of our peptide
MCTIDFNECRFRKC that will mimic the
bound conformation when cyclized. A series
of bis(bromomethyl)naphthalene linkers
(Table 1) will be used for cyclization in order
to vary and optimize the end-to-end distance
of the cysteine residues.

The Hartman lab is also working to increase
binding affinity through various mutations to
the peptide sequence.
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6. References and Recognition
Synthesis of peptide 8.6 (Fig. 3 A)
-automated microwave-enhanced solid-phase
peptide synthesis (SPPS)
Deprotection of s-t-butyl and FMOC groups
(Fig. 3 B)
- In DTT and ammonium bicarbonate
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Cyclization with linker (Fig. 3 C)
- In TCEP and ammonium carbonate

Thanks to VCU’s UROP and the 2015 Clinical and
Translational Research Fellowship Grant for funding.

Fluorescence labeling (Fig. 4 D)
-5-FAM with DCC and HOBt
Figure 1. Crystal Structure of bound peptide 8.6 on
BRCA1
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Figure 3. MALDI-MS of peptide 8.6 at synthesis
(A), deprotection (B), cyclization (C), fluorescence
labeling (D)
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